Nosocomial pneumonia: lessons learned.
暂无分享,去创建一个
[1] Jordi Rello,et al. International study of the prevalence and outcomes of infection in intensive care units. , 2009, JAMA.
[2] F. Tubach,et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial , 2010, The Lancet.
[3] M. Niederman,et al. Respiratory infections and acute lung injury in systemic illness. , 1989, Clinics in chest medicine.
[4] A. Anzueto,et al. Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. , 2006, Chest.
[5] D. Cook,et al. Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia* , 2008, Critical care medicine.
[6] Kelly D Peterson,et al. National Healthcare Safety Network (NHSN) report, data summary for 2009, device-associated module. , 2011, American journal of infection control.
[7] A. Combes,et al. Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. , 2005, American journal of respiratory and critical care medicine.
[8] A. Liapikou,et al. Validation of the American Thoracic Society-Infectious Diseases Society of America guidelines for hospital-acquired pneumonia in the intensive care unit. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] M. Falagas,et al. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis , 2005, Critical care.
[10] M. Niederman. Reexamining quinolone use in the intensive care unit: use them right or lose the fight against resistant bacteria. , 2005, Critical care medicine.
[11] 古谷 良輔,et al. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. , 2008, American journal of respiratory and critical care medicine.
[12] M. Niederman,et al. BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia , 2012, Intensive Care Medicine.
[13] Stijn Vansteelandt,et al. Attributable mortality of ventilator-associated pneumonia: a reappraisal using causal analysis. , 2011, American journal of respiratory and critical care medicine.
[14] D. Cook,et al. The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group. , 1999, American journal of respiratory and critical care medicine.
[15] B. Mourvillier,et al. Early-onset pneumonia after cardiac arrest: characteristics, risk factors and influence on prognosis. , 2011, American journal of respiratory and critical care medicine.
[16] J. Maurer. Epidemiology, Antibiotic Therapy, and Clinical Outcomes in Health Care–Associated Pneumonia: A UK Cohort Study , 2012 .
[17] S. Nseir,et al. Continuous control of tracheal cuff pressure and microaspiration of gastric contents in critically ill patients. , 2011, American journal of respiratory and critical care medicine.
[18] D. Craven,et al. Ventilator-associated tracheobronchitis and pneumonia: thinking outside the box. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[19] Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement, American Thoracic Society, November 1995. , 1996, American journal of respiratory and critical care medicine.
[20] M. Niederman,et al. De-escalation therapy: is it valuable for the management of ventilator-associated pneumonia? , 2011, Clinics in chest medicine.
[21] R. Platt,et al. Objective surveillance definitions for ventilator-associated pneumonia* , 2012, Critical care medicine.
[22] R. Wunderink,et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[23] R. Platt,et al. Multicenter Evaluation of a Novel Surveillance Paradigm for Complications of Mechanical Ventilation , 2011, PloS one.
[24] Matthew Bidwell Goetz,et al. Impact of clinical guidelines in the management of severe hospital-acquired pneumonia. , 2005, Chest.
[25] M. Klompas,et al. Toward improved surveillance: the impact of ventilator-associated complications on length of stay and antibiotic use in patients in intensive care units. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[26] M. Mathru. Continuous Aspiration of Subglottic Secretions in the Prevention of Ventilator-Associated Pneumonia in the Postoperative Period of Major Heart Surgery , 2009 .
[27] M. Niederman,et al. Healthcare-associated pneumonia is a heterogeneous disease, and all patients do not need the same broad-spectrum antibiotic therapy as complex nosocomial pneumonia , 2009, Current opinion in infectious diseases.
[28] D. Craven,et al. Prophylaxis of ventilator-associated pneumonia: changing culture and strategies to trump disease. , 2008, Chest.
[29] J. Fagon. Biological markers and diagnosis of ventilator-associated pneumonia , 2011, Critical care.
[30] A. Ambergen,et al. Risk factors for pneumonia, and colonization of respiratory tract and stomach in mechanically ventilated ICU patients. , 1996, American journal of respiratory and critical care medicine.
[31] M. Niederman. The argument against using quantitative cultures in clinical trials and for the management of ventilator-associated pneumonia. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[32] B. de Jonghe,et al. Intermittent subglottic secretion drainage and ventilator-associated pneumonia: a multicenter trial. , 2010, American journal of respiratory and critical care medicine.
[33] Gordon Guyatt,et al. Incidence of and Risk Factors for Ventilator-Associated Pneumonia in Critically Ill Patients , 1998, Annals of Internal Medicine.
[34] F. Saulnier,et al. First-generation fluoroquinolone use and subsequent emergence of multiple drug-resistant bacteria in the intensive care unit* , 2005, Critical care medicine.
[35] Ronald N. Jones. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[36] M. Kollef,et al. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[37] R. Auckenthaler,et al. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic "blind" bronchoalveolar lavage fluid. , 1991, The American review of respiratory disease.
[38] D. Mozingo. A randomized trial of diagnostic techniques for ventilator-associated pneumonia. , 2006, The New England journal of medicine.
[39] R. Cantor,et al. Septic shock and respiratory failure in community-acquired pneumonia have different TNF polymorphism associations. , 2001, American journal of respiratory and critical care medicine.
[40] J. Barker. A Randomized Trial of Diagnostic Techniques for Ventilator-Associated Pneumonia , 2008 .
[41] Kara E. Flavin,et al. Variability in antibiotic prescribing patterns and outcomes in patients with clinically suspected ventilator-associated pneumonia. , 2003, Chest.
[42] T. Welte,et al. Nursing-home-acquired pneumonia in Germany: an 8-year prospective multicentre study , 2011, Thorax.
[43] M. Kollef,et al. Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[44] A. Combes,et al. Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[45] T. Walsh,et al. Reducing ventilator-associated pneumonia in intensive care: Impact of implementing a care bundle* , 2011, Critical care medicine.
[46] Richard Platt,et al. Rapid and reproducible surveillance for ventilator-associated pneumonia. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[47] R. Grossman,et al. Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults. , 2008, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.
[48] J. Ramirez,et al. Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: an observational, multicentre cohort study. , 2011, The Lancet. Infectious diseases.
[49] F. Jacobs. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. , 2011, Critical care medicine.
[50] A. Bianco,et al. Prevention of ventilator-associated pneumonia, mortality and all intensive care unit acquired infections by topically applied antimicrobial or antiseptic agents: a meta-analysis of randomized controlled trials in intensive care units , 2011, Critical care.
[51] L. Tsu,et al. Practice patterns for antibiotic de-escalation in culture-negative healthcare-associated pneumonia , 2010, Infection.
[52] W. Cui,et al. Effect of Procalcitonin-Guided Treatment in Patients with Infections: a Systematic Review and Meta-Analysis , 2009, Infection.
[53] Y. Chuang,et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. , 2010, Diagnostic microbiology and infectious disease.
[54] A. Marra,et al. A program for sustained improvement in preventing ventilator associated pneumonia in an intensive care setting , 2012, BMC Infectious Diseases.
[55] J. Rello,et al. New issues and controversies in the prevention of ventilator-associated pneumonia. , 2010, American journal of respiratory and critical care medicine.
[56] Roger Resar,et al. Using a bundle approach to improve ventilator care processes and reduce ventilator-associated pneumonia. , 2005, Joint Commission journal on quality and patient safety.
[57] M. Niederman. The importance of de-escalating antimicrobial therapy in patients with ventilator-associated pneumonia. , 2006, Seminars in Respiratory and Critical Care Medicine.
[58] Q. Lu,et al. Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa. , 2011, American journal of respiratory and critical care medicine.
[59] D. Craven,et al. Ventilator-associated tracheobronchitis: the impact of targeted antibiotic therapy on patient outcomes. , 2009, Chest.
[60] D. Baram,et al. Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit* , 2008, Critical care medicine.
[61] Sanjay Saint,et al. Clinical and economic consequences of ventilator-associated pneumonia: A systematic review , 2005, Critical care medicine.
[62] M. Niederman. Hospital-acquired pneumonia, health care-associated pneumonia, ventilator-associated pneumonia, and ventilator-associated tracheobronchitis: definitions and challenges in trial design. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[63] V L Yu,et al. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. , 2000, American journal of respiratory and critical care medicine.
[64] L. Mandell,et al. Hospital-acquired pneumonia in adults: Diagnosis, assessment of severity, initial antimicrobial therapy, and preventative strategies: A consensus statement , 1996 .
[65] J. Chastre,et al. Nosocomial pneumonia in patients receiving continuous mechanical ventilation. Prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture techniques. , 1989, The American review of respiratory disease.
[66] D. Cook,et al. Correlates of clinical failure in ventilator-associated pneumonia: insights from a large, randomized trial. , 2008, Journal of critical care.
[67] A. Shorr,et al. Ventilator-associated pneumonia: the clinical pulmonary infection score as a surrogate for diagnostics and outcome. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[68] M. Klompas. Is a ventilator-associated pneumonia rate of zero really possible? , 2012, Current opinion in infectious diseases.
[69] D. Nicolau,et al. Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. , 2010, Journal of critical care.
[70] D. Paterson,et al. What's behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance. , 2012, International journal of antimicrobial agents.
[71] Marin H Kollef,et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. , 2002, Chest.
[72] S. Corrao,et al. Clinical impact of broad-spectrum empirical antibiotic therapy in patients with healthcare-associated pneumonia: a multicenter interventional study , 2012, Internal and Emergency Medicine.
[73] J. Bartlett,et al. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia , 2004 .
[74] M. Niederman,et al. Resolution of ventilator-associated pneumonia: Prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome* , 2003, Critical care medicine.
[75] M. Kollef,et al. Diagnostic implications of soluble triggering receptor expressed on myeloid cells-1 in BAL fluid of patients with pulmonary infiltrates in the ICU. , 2009, Chest.
[76] A. Vuagnat,et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. , 1998, American journal of respiratory and critical care medicine.
[77] J. Pépin,et al. Impact of guideline-consistent therapy on outcome of patients with healthcare-associated and community-acquired pneumonia. , 2011, The Journal of antimicrobial chemotherapy.
[78] R. Favory,et al. Antimicrobial treatment for ventilator-associated tracheobronchitis: a randomized, controlled, multicenter study , 2008, Critical care.
[79] A. Anzueto,et al. Silver-coated endotracheal tubes and incidence of ventilator-associated pneumonia: the NASCENT randomized trial. , 2008, JAMA.
[80] D. Dreyfuss,et al. Prospective study of nosocomial pneumonia and of patient and circuit colonization during mechanical ventilation with circuit changes every 48 hours versus no change. , 1991, The American review of respiratory disease.
[81] Jordi Rello,et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. , 2002, Chest.
[82] T. Karchmer,et al. Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia. , 2006, Chest.
[83] F. Saulnier,et al. Nosocomial tracheobronchitis in mechanically ventilated patients: incidence, aetiology and outcome , 2002, European Respiratory Journal.
[84] A. Anzueto,et al. Guideline-concordant therapy and outcomes in healthcare-associated pneumonia , 2011, European Respiratory Journal.
[85] Michel Wolff,et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. , 2003, JAMA.
[86] A. Anzueto,et al. Incidence, risk factors, and outcome of ventilator-associated pneumonia. , 2006, Journal of critical care.
[87] A J DeRiso,et al. Chlorhexidine Gluconate 0.12% Oral Rinse Reduces the Incidence of Total Nosocomial Respiratory Infection and Nonprophylactic Systemic Antibiotic Use in Patients Undergoing Heart Surgery , 1996, Chest.
[88] A. E. El Solh,et al. Indicators of potentially drug-resistant bacteria in severe nursing home-acquired pneumonia. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.